Personalized vaccine for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a personal vaccine made from your own tumor's unique markers (neoantigens) to help your immune system fight triple-negative breast cancer. It's for people who've already had standard treatment and whose tumor markers can be matched to a custom vaccine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with triple-negative breast cancer (a type that doesn't have the usual hormone receptors).
- You have already received standard treatment (like chemo, radiation, or surgery).
- Your tumor's unique markers (called neoantigens) have been found and a custom vaccine made from them can be created.
- You are healthy enough: your daily activity level is at 70% or better on a standard scale.
- You are not pregnant or breastfeeding, and don’t have serious heart, kidney, or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help prevent your high-risk triple-negative breast cancer from coming back. It is for people who had significant tumor left after standard chemotherapy and surgery.
This trial tests a personalized cancer vaccine for triple negative breast cancer. It is given alongside standard chemotherapy and immunotherapy to help your immune system fight the cancer.
This trial tests a personalized cancer vaccine (NECVAX-NEO1) given along with standard chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. The vaccine is customized to target specific mutations in your tumor, aiming to boost your immune system and improve treatment outcomes.
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
This early-phase trial tests a personalized immune treatment made from your tumor’s specific “neoantigen” targets (small pieces the immune system can recognize), plus an immune-boosting medicine. It aims to help control certain cancers by training your immune system to attack your tumor.
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Hear when a new Breast Cancer Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.